



Medtronic, Inc.
18000 Devonshire Street
Northridge, CA 91325-1219
www.medtronic.com

Request for Confidentiality

FCC Form 442: File Number 0160-EX-PL-2013
Confirmation Number EL745119

Attention: Application Examiner

Dear Sir or Madam,

In accordance with 47 CFR §0.459 (b), Medtronic Diabetes requests that EXHIBIT A submitted in the application for an Experimental License be held confidential and not be made available for public inspection for the following reasons:

- (1) **Identification of the specific information for which confidential treatment is sought:** Medtronic requests the information disclosed in EXHIBIT A be kept confidential.
- (2) **Identification of the Commission proceeding in which the information was submitted or a description of the circumstances giving rise to the submission:** Medtronic's application for an Experimental License Form 442 File Number 0160-EX-PL-2013.
- (3) **Explanation of the degree to which the information is commercial or financial, or contains a trade secret or is privileged:** The request for confidentiality pertains to information that addresses both commercial and trade secret concerns.
- (4) **Explanation of the degree to which the information concerns a service that is subject to competition:** the information disclosed in EXHIBIT A concerns the development of devices for the medical electronics industry. The medical electronics industry is highly competitive, and developing products for this industry involves a substantial degree of financial investment and financial risk.
- (5) **Explanation of how the disclosure of the information could result insubstantial competitive harm:** Disclosure of the information in EXHIBIT A will inform our competitors of technology we're employing to address a competitive market.
- (6) **Identification of any measures taken by the submitting party to prevent unauthorized disclosure:** Medtronic maintains Non-Disclosure Agreements (NDA's) with all participants in the proposed research project, and vendors supplying equipment related to the research project.
- (7) **Identification of whether the information is available to the public and the extent of any previous disclosure of the information to third parties:** As of this date, the information disclosed in EXHIBIT A has not been made available to the public by Medtronic. All other disclosures to third parties are protected by NDA's.
- (8) **Justification of the period during which the submitting party asserts that the material should not be available for public disclosure:** Medtronic requests the material described in EXHIBIT A be withheld for public disclosure for a period of 3 years. This period will provide Medtronic suitable time to develop the product for sale in the market.

- (9) Any other information that the party seeking confidential treatment believes may be useful in assessing whether its request for confidentiality should be granted: None.

List of Exhibits:

- **EXHIBIT A:** Experimental License Narrative Statement. File Number 0160-EX-PL-2013. Submitted as a MSWord document converted to PDF format, and attached to completed form 442.

If you have questions or need further information, please contact the undersigned.

Sincerely,

James L. Henke
Principal Engineer
Medtronic Diabetes
18000 Devonshire Street
Northridge, CA 91325-1219

Tel: 818-576-5677
E-mail: jim.henke@medtronic.com